Drugs / 765IGF-MTX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03175978 | Feb 2018 → Jun 2021 | chronic myelomonocytic leukemia, myelodysplastic syndrome with excess blasts | IGF Oncology, LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 765IGF-MTX | “765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial” NCT03175978 ↗ |
| Modality | Other / unclassified | “insulin-like growth factor-1-methotrexate conjugate” NCT03175978 ↗ |
| Route | Intravenous | “765IGF-MTX at a dose of 0.20 to 2.5 µequivalents per kg is administered as an IV infusion over 1.5 hours” NCT03175978 ↗ |